Anticoagulation

Maria Cristina Beznă , Suzana Dănoiu , Marinela Beznă , et al

Read time: 1 Min

G Torres-Ruiz , P Rojas-Flores , P Carrion Montaner , et al

Read time: 1 Min

Ben Borokhovsky , Perry J Weinstock ,

Read time: 1 Min

Maki Komiyama , Gheorghe-Andrei Dan , Koji Hasegawa ,

Read time: 4 Mins
Radcliffe & CardioNerds @AHA22: The PREVENT-HD Randomized Clinical Trial

Kahtan Fadah, Gregory Piazza,

Watch time: 15m 37s

Diana Gorog, Sotiris Antoniou , Franco Cheng, et al

View from the Thoraxcenter: ESC 22 Late-breaking Science Wrap-up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 19s
ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3m 29s
ESC 22: P2Y12i Vs Aspirin Monotherapy in CAD Pts

Marco Valgimigli,

Watch time: 4m 59s
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3m 57s
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4m 59s
ESC 22: COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts

David Berg,

Watch time: 4m 51s

Kerry Layne , Albert Ferro ,

Julia Sikorska , James Uprichard ,

Mario Petretta , Pierluigi Costanzo , Alberto Cuocolo ,

Justin Ezekowitz, Harriette Van Spall, Dylan L Steen, et al

Watch time: 4h 13m 20s (28 videos)

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 4h 49m 46s (47 videos)

George D Dangas, Adrian P Banning, Davide Cao, et al

Watch time: 3h 30m 28s (17 videos)

Doreen Su-Yin Tan, Gheorghe-Andrei Dan, Oskars Kalējs, et al

Watch time: 1:01:55

Jack Wei Chieh Tan , Derek P Chew , Muhamad Ali SK Abdul Kader , et al

Frédéric Michard ,

Diana Gorog, Sotiris Antoniou , Franco Cheng, et al

Daniel TT Chong , Felicita Andreotti , Peter Verhamme , et al

Han Naung Tun , May Thu Kyaw , Erik Rafflenbeul , et al

Media

Diana Gorog, Sotiris Antoniou , Franco Cheng, et al

ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s

Watch time: 3:52:31

Doreen Su-Yin Tan, Gheorghe-Andrei Dan, Oskars Kalējs, et al

Watch time: 1:01:55

Sotiris Antoniou , Bernard Man Yung Cheung, Krzysztof Filipiak, et al

Watch time: 6h 2m 18s (6 videos)
View from the Thoraxcenter: ACC.22 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 28m 6s

Justin Ezekowitz, Harriette Van Spall, Dylan L Steen, et al

Watch time: 4h 13m 20s (28 videos)
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

Watch time: 7m 44s
ACC 22: Results from the PACIFIC AF Trial

Manesh R Patel,

Watch time: 3m 19s
View from the Thoraxcanter: ACC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 23m 9s
SPLENDOR: Metabolic Surgery and Risk of MACE in NASH

Ali Aminian,

Watch time: 5m 41s
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

George D Dangas,

Watch time: 9m
STOPDAPT-2 ACT: 1-month DAPT Followed by Clopidogrel Monotherapy in ACS

Hirotoshi Watanabe,

Watch time: 5m 43s
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI

Davide Cao,

Watch time: 8m 40s
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

Watch time: 6m 33s
ACC 2021 Discussion: The ISCHEMIA Trial

Gregg Stone, Harriette Van Spall,

Watch time: 15m 2s
ACC 2021 Discussion: The Coalition ACTION Trial

Harriette Van Spall, Renato D Lopes,

Watch time: 16m 3s
Dr Steven Lubitz

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

Watch time: 17m 13s

Media

Radcliffe & CardioNerds @AHA22: The PREVENT-HD Randomized Clinical Trial

Kahtan Fadah, Gregory Piazza,

Watch time: 15m 37s

Diana Gorog, Sotiris Antoniou , Franco Cheng, et al

View from the Thoraxcenter: ESC 22 Late-breaking Science Wrap-up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 19s
ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3m 29s
ESC 22: P2Y12i Vs Aspirin Monotherapy in CAD Pts

Marco Valgimigli,

Watch time: 4m 59s
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3m 57s
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4m 59s
ESC 22: COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts

David Berg,

Watch time: 4m 51s
ESC 22: Milvexian in Addition to Aspirin ＆ Clopidogrel for Secondary Stroke

Mukul Sharma,

Watch time: 6m 26s
ESC 22: PACIFIC-AMI: FXIa Inhibitor on Top of DAPT After AMI

John Alexander,

Watch time: 4m 22s
ESC 22: Dosing of Asundexian in Pts With Non-Cardioembolic Ischemic Stroke

Ashkan Shoamanesh,

Watch time: 7m 9s
ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s

Watch time: 3:52:31

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 4h 49m 46s (47 videos)
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24m 27s

Doreen Su-Yin Tan, Gheorghe-Andrei Dan, Oskars Kalējs, et al

Watch time: 1:01:55

Sotiris Antoniou , Bernard Man Yung Cheung, Krzysztof Filipiak, et al

Watch time: 6h 2m 18s (6 videos)
View from the Thoraxcenter: ACC.22 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 28m 6s

Justin Ezekowitz, Harriette Van Spall, Dylan L Steen, et al

Watch time: 4h 13m 20s (28 videos)
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

Watch time: 7m 44s
ACC 22: Results from the PACIFIC AF Trial

Manesh R Patel,

Watch time: 3m 19s
View from the Thoraxcanter: ACC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 23m 9s

George D Dangas, Adrian P Banning, Davide Cao, et al

Watch time: 3h 30m 28s (17 videos)
SPLENDOR: Metabolic Surgery and Risk of MACE in NASH

Ali Aminian,

Watch time: 5m 41s
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

George D Dangas,

Watch time: 9m
RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients

Harald Thune Jorstad,

Watch time: 5m 11s
STOPDAPT-2 ACT: 1-month DAPT Followed by Clopidogrel Monotherapy in ACS

Hirotoshi Watanabe,

Watch time: 5m 43s
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI

Davide Cao,

Watch time: 8m 40s
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

Watch time: 6m 33s
EuroPCR 2021: Findings From the POEM Study

Giulio G Stefanini,

Watch time: 8m 8s

Articles

Dual Antiplatelet Therapy in CAD

Christopher N Floyd

,

Published:

26 February 2020

Citation:

European Cardiology Review 2020;15:e08.

DOI:

https://doi.org/10.15420/ecr.2019.09
  • Views: Views 2182
  • Downloads: Downloads 59
  • Citations: 7

Antithrombotic Therapy After TAVI

Leslie Marisol Lugo

,

Rafael Romaguera

,

Joan Antoni Gómez-Hospital

,

José Luis Ferreiro

,

Published:

26 February 2020

Citation:

European Cardiology Review 2020;15:e09.

DOI:

https://doi.org/10.15420/ecr.2019.10
  • Views: Views 1201
  • Downloads: Downloads 38
  • Citations: 8

DOACs in Chronic Coronary Syndromes

Emmanuel Sorbets

,

Philippe Gabriel Steg

,

Published:

26 February 2020

Citation:

European Cardiology Review 2020;15:e10.

DOI:

https://doi.org/10.15420/ecr.2018.24.2
  • Views: Views 839
  • Downloads: Downloads 60
  • Citations: 2

Personalised Approaches to Improving the Effect of Anti-platelet Agents

Lucas C Godoy

,

Michael E Farkouh

,

Published:

18 December 2019

Citation:

European Cardiology Review 2019;14(3):179–80

DOI:

https://doi.org/10.15420/ecr.2019.14.3.GE1
  • Views: Views 198
  • Downloads: Downloads 10